

Dear Editor,

My coauthors and I are pleased to submit our manuscript, "Systematic Literature Review of the Antitumor Effect of Octreotide in Neuroendocrine Tumors," for consideration for publication in World Journal of Meta-Analysis. This submission is a resubmission after receiving reviewers comments from our submission to World Journal of Gastroenterology.

The reviewer's comments and our responses are as follows:

1. "If disease progression, treatment with SSA should be continued in combination with any of the subsequent options or not. Please mention about this clinical question." – We have addressed this comment by expanding on the NCCN guidelines to include the statement: "For patients with unresectable NETs of the pancreas and/or distant metastases who have progressed on treatment with an SSA, octreotide or lanreotide may be continued in combination with everolimus, sunitinib, or chemotherapy." This statement can be found on page 8/9 and on page 16
2. "Does octreotide effect except mid-gut. However, these table and main text does not mention about primary site. Please clarify the primary site in table and mention about this point in discussion." – We have added primary site in the tables where it wasn't already noted and made clarifications on page 15.

All changes in the revised manuscript have been noted in yellow highlight.

This manuscript has not been published in any other journal and is not under consideration elsewhere. All authors equally contributed to the development of this manuscript and meet the criteria for authorship as outlined by the International Committee of Medical Journal Editors. As the corresponding author, I confirm that I had full access to all aspects of this research and the writing process, and I take full responsibility for the content of this work.

This study was completed under a research contract between Novartis Pharmaceuticals and RTI Health Solutions and was funded by Novartis Pharmaceuticals. Beilei Cai and Raoudha Soufi-Mahjoubi are employees of Novartis Pharmaceuticals; Stephanie, Catherine Copley-Merriman, Kelly Wright, and Colleen Castro are salaried employees of RTI Health Solutions.

We appreciate your consideration of our manuscript and look forward to your response.

Sincerely,

Stephanie Barrows